Prevalence of nodal metastases in the individual lymph node stations for different T-stages in gastric cancer: a systematic review - Scorecard - MDSpire

Prevalence of nodal metastases in the individual lymph node stations for different T-stages in gastric cancer: a systematic review

  • By

  • M. H. S. de Jong

  • S. S. Gisbertz

  • M. I. van Berge Henegouwen

  • W. A. Draaisma

  • August 13, 2022

  • 0 min

Share

Clinical Scorecard: Distribution of Nodal Metastases Across Lymph Node Stations by T-Stage in Gastric Cancer: A Systematic Review

At a Glance

CategoryDetail
ConditionGastric cancer with lymph node metastases
Key MechanismsTumor invasion depth (T-stage) correlates with prevalence and distribution of lymph node metastases; extent of lymphadenectomy influences recurrence and survival
Target PopulationPatients with operable gastric cancer undergoing surgical treatment
Care SettingSurgical oncology and gastroenterology clinical settings

Key Highlights

  • Gastric cancer remains the fifth most common cancer worldwide and third leading cause of cancer mortality.
  • Lymph node involvement strongly influences recurrence rates (20%-50%) and prognosis in gastric cancer.
  • Extent of lymphadenectomy (D1 vs D2) impacts loco-regional recurrence, survival, and surgical morbidity/mortality.

Guideline-Based Recommendations

Diagnosis

  • Use AJCC 7th edition for T-stage classification in gastric cancer.
  • Classify lymph node stations per Japanese Gastric Cancer Association system.
  • Assess nodal metastases prevalence per individual lymph node station by T-stage.

Management

  • Perform D1 lymphadenectomy for T1a tumors and well-differentiated, <1.5 cm T1b tumors not meeting endoscopic resection criteria.
  • Consider D2 lymphadenectomy for more advanced T-stages to reduce loco-regional recurrence and improve survival.
  • Endoscopic resection is feasible for early gastric tumors meeting strict criteria (e.g., T1a, well-differentiated, ≤2 cm, non-ulcerated).

Monitoring & Follow-up

  • Monitor for recurrence given high rates post-gastrectomy, especially in patients with lymph node involvement.
  • Balance risk of lymph node metastases with surgical morbidity when deciding extent of lymphadenectomy.

Risks

  • D2 lymphadenectomy is associated with higher morbidity (43%-46%) and mortality (10%-13%) compared to D1 lymphadenectomy.
  • Risk of lymph node metastases increases substantially from T1 (8%-31%) to T2-T4 tumors (45%-90%).

Patient & Prescribing Data

Patients with operable gastric cancer stratified by T-stage

Tailored lymphadenectomy extent based on T-stage and tumor characteristics balances oncologic benefit and surgical risk.

Clinical Best Practices

  • Use multidisciplinary approach incorporating tumor biology, stage, and location to guide extent of lymphadenectomy.
  • Apply Japanese Gastric Cancer Association lymph node station classification for surgical planning.
  • Consider endoscopic resection for early-stage tumors meeting established criteria to avoid unnecessary surgery.
  • Perform systematic quality assessment of studies when reviewing evidence to inform clinical decisions.

References

Original Source(s)

Related Content